NRX

Rumble Reports First Quarter 2023 Results

Retrieved on: 
Monday, May 15, 2023
Season, Partnership, BKFC, Bare Knuckle Fighting Championship, Republican National Committee, JiDion, Speech, Culture, IShowSpeed, Internet, Street League Skateboarding, DJ Akademiks, SNL, Android, Social media, NRX, Nitro Rallycross, Acquisition, SLS, RNC, Active users, Maus, Sport, Republican, RAC, Growth, Power Slap, Roku, Mobile phone, Video game, Music, Callin, Rumble

LONGBOAT KEY, Fla., May 15, 2023 (GLOBE NEWSWIRE) -- Rumble Inc. ("Rumble") (NASDAQ: RUM), the popular video-sharing platform, announced today financial results for the fiscal quarter ended March 31, 2023.

Key Points: 
  • ~ Rumble Adds YouTube's Top US Gaming Streamer, IShowSpeed, and Twitch's Most-Subscribed Streamer, Kai Cenat ~
    ~ Acquires Podcasting and Livestreaming Platform Callin, Founded by David Sacks ~
    LONGBOAT KEY, Fla., May 15, 2023 (GLOBE NEWSWIRE) -- Rumble Inc. ("Rumble") (NASDAQ: RUM), the popular video-sharing platform, announced today financial results for the fiscal quarter ended March 31, 2023.
  • First quarter revenue increased over 336% to $17.6 million, compared to $4.0 million in the first quarter of 2022.
  • Average estimated Minutes Watched Per Month ("MWPM") increased 3% in the first quarter of 2023 to 10.8 billion, compared to 10.5 billion in the first quarter of 2022, and 11.1 billion in the fourth quarter of 2022.
  • Hours of uploaded video per day increased 82% to 11,181 in the first quarter of 2023, compared to 6,158 in the first quarter of 2022 and 10,373 in the fourth quarter of 2022.

Rumble Locks in Two Additional Sports Leagues and Emerges as the Leading Platform For Live-Streaming Action Sports

Retrieved on: 
Thursday, March 30, 2023
Sport, UFC, Erosion (morphology), Rumble, Street League Skateboarding, Red Bull Junior Team, NRX, Athlete, Nitro Rallycross, SLS, NASCAR, Ultimate, Power Slap, Social media, Female

Combined with the previously announced agreement in principle for Seasons 2 and 3 of Power Slap, the three leagues represent a major advance into live-action sports distribution by Rumble.

Key Points: 
  • Combined with the previously announced agreement in principle for Seasons 2 and 3 of Power Slap, the three leagues represent a major advance into live-action sports distribution by Rumble.
  • NRX is the next generation of motorsports, featuring the biggest personalities on racing’s most aggressive and epic tracks.
  • This fast-growing league was created by visionary action sports icon, Travis Pastrana, in large part due to his loyal fanbase of over 12 million social media followers.
  • Sports is content in its most authentic form, which is why it belongs on Rumble.”

NurExone Announces Q4 and Full-year 2022 Financial Results and Provides Company Update, Highlighting 143.9% Scientific Research Investment Growth

Retrieved on: 
Thursday, March 30, 2023
Patent, Rat, Reflex, TSX Venture Exchange, Central nervous system, Tetraplegia, United States Patent and Trademark Office, Spinal cord, Frankfurt Stock Exchange, Policy, Exosome, CAD, FSE, Research, Scientific Outlook on Development, Patent Cooperation Treaty, PCT, NRX, Small RNA, TEL, Acquisition, Patient, PTEN, The Company, SCI, Pharmaceutical industry, Cryptocurrency, Medical device

During the year, the Company's cash increased by 11.1%, from US$2.21 million in 2021 to US$2.46 million in 2022.

Key Points: 
  • During the year, the Company's cash increased by 11.1%, from US$2.21 million in 2021 to US$2.46 million in 2022.
  • In Q4 2022, research and development expenses amounted to US$0.38 million, compared to US$0.30 million for the same period in 2021.
  • Financial expenses grew from US$0.01 million in Q4 2021 to US$0.17 million in Q4 2022, due to a change in accounting policy for warrant derivatives.
  • As the Company scales, NurExone intends to continue expanding its patent portfolio in order to strengthen its competitive strength.

NurExone Biologic Reports Additional Positive Preclinical Trial Outcomes with ExoPTEN: 75% of Paralyzed Rats Show Recovery after Acute Spinal Cord Injury Study

Retrieved on: 
Monday, March 20, 2023
Rat, Self-harm, Tetraplegia, Exosome, Diagnosis, Weizmann Institute of Science, FSE, Research, NRX, Paralysis, Friends, TEL, Incidence, Regeneration, PTEN, Patient, Health, SCI, Fig, Disease, Trapping, Dietary supplement, Medical device

(TSXV: NRX) (FSE: J90) (NRX.V) (“NurExone” or the “Company”), disclosed today additional results from an internal preclinical study of its investigational drug ExoPTEN demonstrating effective treatment of 75% of paralyzed rats suffering from spinal cord injuries.

Key Points: 
  • (TSXV: NRX) (FSE: J90) (NRX.V) (“NurExone” or the “Company”), disclosed today additional results from an internal preclinical study of its investigational drug ExoPTEN demonstrating effective treatment of 75% of paralyzed rats suffering from spinal cord injuries.
  • 1)
    ExoPTEN is being developed to be a minimally invasive ExoTherapy for spinal cord injuries (SCI), yielding neuron regeneration and rewiring in traumatically damaged spinal cords.
  • NurExone’s ExoTherapy platform has the potential to revolutionize spinal cord injury treatment and significantly enhance patient outcomes.
  • As comparable therapies are presently unavailable, the Company is dedicated to prioritizing the spinal cord injury community and providing them with this innovative technology.

NurExone Announces Interim Positive Results of Internal Preclinical Study of Proprietary ExoPTEN Drug

Retrieved on: 
Friday, February 17, 2023
Rat, NRX, Spinal cord, Exosome, SCI, PTEN, Patient, Cell, RNA, Tetraplegia, Reflex, FSE, Regeneration, Conference, Pharmaceutical industry

ExoPTEN is being developed by NurExone as a minimally invasive drug, aimed at capitalizing on the $2.9 billion market for acute Spinal Cord Injuries (SCI) ( https://www.reportlinker.com/p05960165/Global-Spinal-Cord-Trauma-Treatme... ).

Key Points: 
  • ExoPTEN is being developed by NurExone as a minimally invasive drug, aimed at capitalizing on the $2.9 billion market for acute Spinal Cord Injuries (SCI) ( https://www.reportlinker.com/p05960165/Global-Spinal-Cord-Trauma-Treatme... ).
  • The current study was designed to assess the impact of ExoPTEN on the motor, reflex, and sensory recovery of rats, following full transection (i.e.
  • (Figs 1-3)
    “The interim results of the study strongly suggest that ExoPTEN yields partial rewiring of the spinal cord in rats, bringing recovered capability,” commented Dr. Lior Shaltiel, CEO of NurExone.
  • The current study assessed ExoPTEN with an improved and modified siRNA (small interfering RNA) sequence as its therapeutic cargo.

NurExone Biologic Inc. Emerges as a Promising Investment Opportunity in Biotechnology

Retrieved on: 
Monday, February 13, 2023
FSE, Diagnosis, Neuron, Exosome, Neurosurgery, Patent, CNS, David Shaltiel, SCI, Tetraplegia, United States Patent and Trademark Office, Therapy, NRX, R, Quality of life, Patient, Paralysis, Injury, Tel Aviv University, Regeneration, Research, Rat, TEL, Fine chemical, Pharmaceutical industry, Medical device, Technion – Israel Institute of Technology

NurExone has established itself as a unique company by possessing both a product in development, ExoPTEN, and an advanced platform for the production and loading of exosomes.

Key Points: 
  • NurExone has established itself as a unique company by possessing both a product in development, ExoPTEN, and an advanced platform for the production and loading of exosomes.
  • This combination aims to position the company ahead of its competitors in terms of effectiveness and efficiency.
  • Exosomes are nanocarriers with the unique ability to carry "cargo" to target specific cells and inflamed tissue, while navigating extracellular spaces and penetrating cell membranes.
  • Exosomes loaded with therapeutic pharmaceutical cargo (ExoTherapy) are a highly promising drug delivery platform.

United States Patent Office Allows Patent to Exosome Biomedical Company Nurexone

Retrieved on: 
Friday, January 13, 2023
NRX, Cell, PTEN, PCT, Patent, CVE, TSX Venture Exchange, Seminal vesicles, Meeting, FRA, Invention, Sirna, Patient, Plan, Exosome, Tel Aviv University, IP, Pharmaceutical industry

HAIFA, Israel and CALGARY, Alberta, Jan. 13, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (NRX:CVE) (J90:FRA) (the “Company” or “NurExone”), a biopharmaceutical company developing biologically-guided exosome therapy (“ExoTherapy”) for patients with traumatic spinal cord injuries, has received a notice of allowance from the United States Patent and Trademark Office (“USPTO”) for U.S. Patent Application NO.

Key Points: 
  • HAIFA, Israel and CALGARY, Alberta, Jan. 13, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (NRX:CVE) (J90:FRA) (the “Company” or “NurExone”), a biopharmaceutical company developing biologically-guided exosome therapy (“ExoTherapy”) for patients with traumatic spinal cord injuries, has received a notice of allowance from the United States Patent and Trademark Office (“USPTO”) for U.S. Patent Application NO.
  • The Patent covers and protects NurExone Exo-PTEN technology, and its drug composition as well as methods for non-invasive intranasal administration of exosome-based treatment.
  • The Company intends to file additional patent applications with the USPTO as well as additional international patent applications (PCT) in order to further strengthen NurExone’s intellectual property portfolio.
  • The Patent was submitted by the Technion-Israel Institute of Technology and Ramot, a Tel Aviv University's technology transfer company and is part of NurExone’s licensed intellectual property portfolio.

Future Markets Research Releases Commentary on NurExone Biologic Inc, An Emerging Leader in The Exosomal Treatment of Spinal Cord Injury

Retrieved on: 
Sunday, October 2, 2022
Professional Services, Health, Finance, General Health, Research, Science, Biotechnology, FSE, Mortality, SCI, Exosome, CAGR, Indian stock exchange, Spinal cord, USD, US, NRX, Accident, Therapy, Compound, Health insurance, Fine chemical

The Future Markets Research Tank (FMRT) is proud to release market commentary on NurExone Biologic (TSXV: NRX) (FSE: J90), an innovative biotechnology company poised to disrupt the spinal cord injury treatment industry and the exosome research landscape.

Key Points: 
  • The Future Markets Research Tank (FMRT) is proud to release market commentary on NurExone Biologic (TSXV: NRX) (FSE: J90), an innovative biotechnology company poised to disrupt the spinal cord injury treatment industry and the exosome research landscape.
  • To read the full report click here , or follow the link: https://bit.ly/3UW9TzC
    Each year, hundreds of thousands of people suffer from spinal cord injury.
  • In addition, poor medical care and the lack of availability of effective treatments contribute to an increase in SCI patient mortality and disability.
  • With their unique ExoTherapies, NurExone is making significant advancements towards becoming a market leader in exosome-based treatment for acute spinal cord injuries.

Medigus: Polyrizon Signed an Agreement with Nurexone for Intranasal Administration of Cutting - Edge Therapy for Spinal Cord Injuries

Retrieved on: 
Monday, July 18, 2022
SEC, Patient, Solution, NRX, Sirna, Quality of life, GLOBE, Collaboration, Digital, Private Securities Litigation Reform Act, Technology, Robotics, Ownership, Environment, Exosome, Human, C&C, T&T, Industry, Respiratory system, Allergen, USD, Capture, MDGS, Trap, SCI, Nose, Pharmaceutical industry, Technion – Israel Institute of Technology

Tel Aviv, Israel, July 18, 2022 (GLOBE NEWSWIRE) -- Medigus Ltd. (Nasdaq: MDGS), a technology company engaged in advanced medical solutions, innovative internet technologies, and electric vehicle and charging solutions, announced today that Polyrizon Ltd. ("Polyrizon"), an Israeli biotech company that specializes in innovative intranasal products in which Medigus owns 37.03%, signed a binding Collaboration Agreement with NurExone Biologic Inc. (TSXV: NRX), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal cord injuries ("NurExone").

Key Points: 
  • Under the Collaboration Agreement, Polyrizon will use its advanced Trap and Target platform to develop formulations, conduct analytical development and produce technical batches of a tailored intranasal delivery system.
  • The intranasal system is being designed for efficient delivery of Nurexones ExoTherapy to patients with traumatic spinal cord injuries (SCI) and may also be relevant to other indications through intranasal exosome delivery.
  • In advance stages of the collaboration, Polyrizon may assist NurExone with regulatory submissions for the United States and Europe.
  • Polyrizon Ltd. is a clinical development stage biotech company focused on the development and commercialization of innovative intranasal products.

NurExone Biologic Inc. Opens the Market

Retrieved on: 
Tuesday, July 5, 2022
Patient, TSX, TOC, Paralysis, Company, Business development, TSX Venture Exchange, NRX, Sirna, Quality of life, TMX

TORONTO, July 4, 2022 /CNW/ - Representatives from NurExone Biologic Inc. ("NurExone" or the "Company") (TSXV: NRX) and their team joined Yossi Boker, TMX Head of Business Development, Israel to celebrate the Company's listing on TSX Venture Exchange and open the market.

Key Points: 
  • TORONTO, July 4, 2022 /CNW/ - Representatives from NurExone Biologic Inc. ("NurExone" or the "Company") (TSXV: NRX) and their team joined Yossi Boker, TMX Head of Business Development, Israel to celebrate the Company's listing on TSX Venture Exchange and open the market.
  • NurExone is a pharmaceutical company developing a biological extracellular vesicles (EV)-based technology drug platform.
  • For Market Openings:Media may pick up a feed from the TOC (television operations centre) for all market open ceremonies.
  • The feed is named TSX Transmit 1 (SD-SDI) and is produced at the TMX Broadcast Centre and sent live to the TOC.